Bluefin Capital Management LLC Buys 869 Shares of Pfizer Inc. (NYSE:PFE)

Bluefin Capital Management LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 9.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,569 shares of the biopharmaceutical company’s stock after purchasing an additional 869 shares during the quarter. Bluefin Capital Management LLC’s holdings in Pfizer were worth $296,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Wellington Management Group LLP raised its position in shares of Pfizer by 4.9% in the 4th quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock valued at $6,886,849,000 after buying an additional 11,099,024 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Pfizer by 3.2% in the second quarter. Massachusetts Financial Services Co. MA now owns 71,794,056 shares of the biopharmaceutical company’s stock valued at $2,008,798,000 after buying an additional 2,241,609 shares in the last quarter. Van ECK Associates Corp raised its stake in Pfizer by 1.8% during the second quarter. Van ECK Associates Corp now owns 16,104,088 shares of the biopharmaceutical company’s stock worth $450,593,000 after acquiring an additional 290,760 shares in the last quarter. Federated Hermes Inc. lifted its holdings in shares of Pfizer by 3.3% in the second quarter. Federated Hermes Inc. now owns 14,923,545 shares of the biopharmaceutical company’s stock worth $417,561,000 after acquiring an additional 470,003 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in shares of Pfizer by 2.4% during the 2nd quarter. Envestnet Asset Management Inc. now owns 10,260,067 shares of the biopharmaceutical company’s stock valued at $287,077,000 after purchasing an additional 238,850 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.9 %

NYSE:PFE opened at $28.67 on Wednesday. The firm has a fifty day simple moving average of $29.28 and a two-hundred day simple moving average of $28.31. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $34.11. The stock has a market capitalization of $162.46 billion, a price-to-earnings ratio of -477.83, a PEG ratio of 1.27 and a beta of 0.68. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same period in the prior year, the business earned $0.67 EPS. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on PFE. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. UBS Group raised their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. StockNews.com cut Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday. Barclays boosted their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Nine investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.